Evidence map›Paper›PMID 40063144›Full record

ArticleEuropean journal of nutrition2025

6-Shogaol, a neuro-nutraceutical derived from ginger, alleviates motor symptoms and depression-like behaviors and modulates the release of monoamine neurotransmitters in Parkinson's disease mice.

Jin Hee Kim, Hae-Jee Yoon, Yujin Choi, Jin Se Kim, In Gyoung Ju, Hyeyoon Eo, Seungmin Lee, Jun-Young Cho, Boyoung Y Park, Seon-Pyo Hong and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Green in situ reduction synthesis of CuAnalytical and bioanalytical chemistry · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jin Hee KimDepartment of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Hae-Jee YoonDepartment of Integrated Drug Development and Natural Products, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Yujin ChoiDepartment of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Jin Se KimDepartment of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
In Gyoung JuDepartment of Oriental Pharmaceutical Science and Kyung Hee East-West Pharmaceutical Research Institute, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.
Hyeyoon EoDepartment of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Seungmin LeeDepartment of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Jun-Young ChoDepartment of Fundamental Pharmaceutical Science, Kyung Hee University, Seoul, 02447, Republic of Korea.
Boyoung Y ParkDepartment of Fundamental Pharmaceutical Science, Kyung Hee University, Seoul, 02447, Republic of Korea.
Seon-Pyo HongDepartment of Integrated Drug Development and Natural Products, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea.
Hi-Joon ParkDepartment of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea.
Myung Sook OhDepartment of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, 02447, Republic of Korea. msohok@khu.ac.kr.ORCID http://orcid.org/0000-0001-8189-4066

Funding

Ministry of Health and Welfare HI23C1371National Research Foundation of Korea 2022M3A9B6017813
6 · The paper itself

Abstract

purposeParkinson's disease (PD) disrupts the regulation of neurotransmitters in the brain, causing patients to experience not only motor symptoms but also non-motor symptoms such as depression. 6-shogaol (6S) is a potential neuro-nutraceutical derived from ginger, and is known to ameliorate motor symptoms by suppressing inflammation in PD mice. In this study, we investigated whether 6S can attenuate motor symptoms and depression-like behaviors through neurotransmitter regulation and to elucidate which neurotransmitters are intimately correlated with these effects.

methodsC57BL/6 J mice were injected with 30 mg/kg of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 5 d to induce PD. 6S was administered via oral gavage for 11 d, including the MPTP injection period.

results6S alleviated MPTP-induced motor symptoms and depression-like behaviors. MPTP injection decreased the levels of seven neurotransmitters in the striatum and four neurotransmitters in the hippocampus. Administration of 6S increased striatal dopamine, serotonin, and norepinephrine levels and hippocampal dopamine, norepinephrine, serotonin, and γ-aminobutyric acid levels. Moreover, correlation analysis shown that the motor symptom improvement effect of 6S was associated with striatal dopamine, norepinephrine, serotonin, and 5-hydroxyindoleacetic acid levels. The effect of 6S on depressive-like behavior was significantly correlated with striatal dopamine metabolites and serotonin and hippocampal dopamine, norepinephrine, and serotonin. Immunohistochemistry showed that 6S upregulated the expression of the vesicular monoamine transporter 2, which was reduced by MPTP in the striatum and hippocampus.

conclusionThis study demonstrated that 6S improved motor symptoms and depression-like behaviors by regulating the release of monoamine neurotransmitters.

Indexed as

Biogenic MonoaminesCatecholsDepressionNeurotransmitter AgentsParkinson DiseaseZingiber officinale1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsBehavior, AnimalCorpus StriatumDisease Models, AnimalDopamineHippocampusMaleMiceMice, Inbred C57BL1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineBiogenic MonoaminesCatecholsDopamineNeurotransmitter AgentsSerotoninshogaol6-shogaolDepressionMonoamine neurotransmitterParkinson’s disease

Identifiers

PMID40063144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.